Wockhardt Limited (NSE:WOCKPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 213.90B |
| Revenue (ttm) | 30.01B |
| Net Income (ttm) | -1.91B |
| Shares Out | 162.47M |
| EPS (ttm) | -12.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,001 |
| Average Volume | 677,768 |
| Open | 1,392.00 |
| Previous Close | 1,385.15 |
| Day's Range | 1,315.90 - 1,404.95 |
| 52-Week Range | 490.15 - 1,679.90 |
| Beta | 1.72 |
| RSI | 41.23 |
| Earnings Date | Feb 13, 2025 |
About Wockhardt
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram nega... [Read more]
Financial Performance
In 2023, Wockhardt's revenue was 28.30 billion, an increase of 6.51% compared to the previous year's 26.57 billion. Losses were -4.63 billion, -17.17% less than in 2022.
Financial StatementsNews
Wockhardt reports Q3 Results: Revenue up 3% to Rs 721 crore, Net profit at Rs 20 crore vs loss of Rs 86 crore YoY
Pharmaceutical major Wockhardt Limited reported its financial results for the quarter ending December 31, 2024, showcasing a remarkable turnaround in profitability. The company posted a net profit of ...
Wockhardt shares surge 10% as flagship antibiotic Zaynich demonstrates breakthrough clinical success
Wockhardt Limited witnessed a 10% surge in its share price after its flagship antibiotic, Zaynich® (Zidebactam/Cefepime, WCK 5222), achieved a major milestone in clinical trials. The drug demonstrated...
Wockhardt’s Zaynich achieves 96.8% clinical cure rate, sets new benchmark in Phase III global study
Wockhardt Limited’s flagship antibiotic, Zaynich® (Zidebactam/Cefepime, WCK 5222), has achieved a significant milestone in its development, delivering the highest-ever efficacy among FDA-approved nove...
Wockhardt’s Zaynich achieves 97% efficacy in treating resistant infections
Wockhardt Limited has announced that its proprietary antibiotic combination, Zaynich® (Zidebactam/Cefepime, WCK 5222), demonstrated over 97% clinical efficacy in a pivotal study targeting carbapenem-r...
Wockhardt shares surge nearly 5% after CDSCO approval for revolutionary antibiotic Miqnaf
Shares of Wockhardt Limited climbed by nearly 5% to ₹1,515 after the company announced the approval of its novel oral antibiotic, Miqnaf® (Nafithromycin), by the Central Drugs Standard Control Organiz...
Stocks in Focus Today on January 4, 2025: Wockhardt, NHPC, RITES, IRFC, Hind Zinc and more
Foreign Institutional Investors (FIIs) were key drivers of market momentum with net inflows of ₹1,506.75 crore. FIIs purchased shares worth ₹13,402.85 crore while selling shares worth ₹11,896.10 crore...
Wockhardt launches new-generation oral antibiotic Miqnaf for community-acquired bacterial pneumonia (CABP)
Wockhardt Limited has announced the approval of its new oral antibiotic, Miqnaf® (Nafithromycin), by the Central Drugs Standard Control Organization (CDSCO) for treating community-acquired bacterial p...
Wockhardt shares surge over 4% on successful Zaynich treatment for drug-resistant infections
Wockhardt Ltd’s shares surged 4.16% to ₹1,455 in Monday’s session following the successful use of its breakthrough antibiotic Zaynich™ (Zidebactam/Cefepime, WCK 5222) in treating a critical US patient...
Wockhardt shares jump 4% on Q2 FY25 results
Wockhardt’s stock saw a 4% increase after the company reported promising Q2 FY25 results. Revenue from operations grew by 7.4% year-over-year to ₹809 crore, up from ₹753 crore in Q2 FY24. Sequentially...
Workhardt Q2 FY25 Results: Revenue up 7.43% YoY to Rs 809 crore, Net Loss widens to Rs 22 crore
Wockhardt Limited announced its Q2 FY25 financial results, reflecting moderate revenue growth alongside persistent losses. Here are the key highlights of Wockhardt’s performance for the quarter: Reven...
Wockhardt Q2 FY25 results: Stock drops 3% ahead of result announcement
Wockhardt’s stock saw a decline of over 3% as investors await its Q2 FY25 results. The shares opened at ₹1,198, reaching a high of ₹1,198 before slipping to a low of ₹1,140.10 during trading. Despite ...
Wockhardt files Insulin Aspart injection with DCGI, reinforcing diabetes management commitment
Wockhardt, a global pharmaceutical and biotechnology company, has filed its fast-acting insulin analog, Aspart injection (ASPARAPIDTM), with the Drugs Controller General of India (DCGI). This developm...
Wockhardt’s WCK 6777 earns Fast Track Designation from USFDA
The US FDA granted Wockhardt’s new antibiotic, WCK 6777, Fast Track designation for the treatment of complicated urinary tract infections and intra-abdominal infections. It successfully completed Phas...
Wockhardt founder Dr. Habil Khorakiwala honored with lifetime achievement award
Dr. Habil Khorakiwala, the founder and chairman of Wockhardt, has been awarded the Lifetime Achievement Award at the 10th Integrated Health & Wellbeing (IHW) Summit held in Dubai. This prestigious awa...
Wockhardt’s Zaynich™ treats drug-resistant meningitis in clinical case
Wockhardt Limited has announced a significant breakthrough with its investigational drug Zaynich™ (Zidebactam/Cefepime), which has successfully cured a complex case of meningitis caused by a pan-drug ...
Wockhardt refutes Cong allegations of 'rent payments' to Sebi chief
Wockhardt has firmly denied allegations of improper rent payments involving Carol Info Services and disputed claims linking it to certain SEBI orders. Congress media head Pawan Khera raised concerns a...
Buch received rental income from entity under Sebi probe, says Congress
The Public Accounts Committee may summon Sebi chairperson Madhabi Puri Buch following Congress's allegations of conflict of interest. They claim she earned over Rs 2 crore in rental income from a comp...
'What is he afraid of?': Congress on PM Modi's 'inaction' over allegations against Sebi chief
Congress has leveled corruption allegations against Sebi chief Madhabi Puri-Buch, claiming she rented her property to a company regularly dealing with Sebi. Congress leader Pawan Khera pointed out tha...